Skip to content

PENG and LFCN Block Versus Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty

Efficacy and Safety of Ultrasound Guided Combined Pericapsular Nerve Group Block and Lateral Femoral Cutaneous Nerve Versus Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty: Randomized Clinical Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05652075
Enrollment
66
Registered
2022-12-15
Start date
2023-01-01
Completion date
2024-02-01
Last updated
2023-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Pain, Regional Block

Keywords

PENG, lumber plexus, hip surgery

Brief summary

Regional anesthesia for postoperative analgesia in THA includes epidural anesthesia and peripheral nerve blocks. However epidural anesthesia has a great role in THA, it has become restricted as perioperative antithrombotic drugs are generally used for orthopedic patients. the study aim to evaluate and compare efficacy and safety of pericapsular nerve group block (PENG) block and lateral femoral cutaneous nerve versus Lumbar plexus block on postoperative analgesia in hip surgery.

Interventions

PROCEDUREpericapsular nerve group and lateral femoral cutaneous nerve block

Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.

Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

(ASA) physical status I to III scheduled for hip surgery aged (30-70) years

Exclusion criteria

* Drug allergy, * Morbid obesity (BMI \>40 kg/m2), * Coagulopathy, * Psychiatric disorder, * Opioid dependence, * Patient refusal to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Visual analogue scale pain scores24 hourpain score from 0-10 which 0 mean no pain and 10 the worst pain

Secondary

MeasureTime frameDescription
first analgesic request24 hourtime to demand nalbuphine
total analgesic consumption24 hourtotal nalbuphine in mg consumed in the first day
First time to ambulate24 hoursfirst time to move

Countries

Egypt

Contacts

Primary Contacthassan m. hetta, lecturer
hassan.hetta@mu.edu.eg1010901114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026